{
    "medicine_id": "62528e44a70a4c1dc19289a366aef159466c46da",
    "platform_id": "DB11332",
    "metadata": {
        "name": "Surfaxin Suspension",
        "composition": "Sinapultide",
        "clinical_particulars": {
            "therapeutic_indications": "Infant respiratory distress syndrome L2502 L2506 L2507 L2511",
            "contraindications": {
                "disease": "If respiration ventilation or oxygenation is clearly affected after an accidental overdose aspirate as much of the suspension as possible and provide the infant with supportive treatment L2507",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Windtree s KL4 surfactant technology produces a synthetic surfactant that is structurally similar to human pulmonary surfactant and contains a proprietary synthetic peptide KL4 sinapultide cost a 21 amino acid peptide that is formulated to mimic the essential attributes of the human surfactant protein B SP B This protein is one of four surfactant proteins and is the most important for the adequate function of the respiratory system Windtree has demonstrated in pre clinical studies that KL4 surfactant may possess certain other beneficial properties including alteration of the inflammatory process antimicrobial properties as well as non immunogenicity L2511",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}